Xiaowei Zhang

Xiaowei Zhang

Auto-generated profile, based on publicly available information

Xiaowei Zhang

Department of Bioengineering, Stanford University, Stanford, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LGLucie Y. Guo
Lucie Y. Guo
JBJing Bian
Jing Bian
ADAlexander E. Davis
Alexander E. Davis
PLPingting Liu
Pingting Liu
HKHannah R. Kempton
Hannah R. Kempton
LQLei S. Qi
Lei S. Qi

9 January 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
XJXin Jin
Xin Jin
XZXiaowei Zhang
Xiaowei Zhang
XDXuejing Ding
Xuejing Ding
TTTian Tian
Tian Tian
CTChao-Kai Tseng
Chao-Kai Tseng
FBFan Bai
Fan Bai
As an important free energy source, the membrane voltage (V m ) regulates many essential physiological processes in bacteria. However, in comparison with eukaryotic cells, knowledge of bacterial electrophysiology is very limited. Here, we developed a set of novel genetically encoded bacterial V m sensors which allow single-cell recording of bacterial V m dynamics in live cells with high temporal resolution. Using these new sensors, we reveal the electrically “excitable” and “resting” states of bacterial cells dependent on their metabolic status. In the electrically excitable state, frequent hyperpolarization spikes in bacterial V m are observed, which are regulated by Na + /K + ratio of the medium and facilitate increased antibiotic tolerance. In the electrically resting state, bacterial V m displays significant cell-to-cell heterogeneity and is linked to the cell fate after antibiotic treatment. Our findings demonstrate the potential of our newly developed voltage sensors to reveal the underpinning connections between bacterial V m and antibiotic tolerance.

24 September 2025 in bioRxiv
Verified
Preprint
Open access
LFLuis Santiago Mille Fragoso
Luis Santiago Mille Fragoso
CDClaudia L. Driscoll
Claudia L. Driscoll
JWJohn N. Wang
John N. Wang
HDHaoyu Dai
Haoyu Dai
TWTalal Widatalla
Talal Widatalla
XGXiaojing J. Gao
Xiaojing J. Gao
Obtaining novel antibodies against specific protein targets is a widely important yet experimentally laborious process. Meanwhile, computational methods for antibody design have been limited by low success rates that currently require resource-intensive screening. Here, we introduce Germinal, a broadly enabling generative pipeline that designs antibodies against specific epitopes with nanomolar binding affinities while requiring only low-n experimental testing. Our method co-optimizes antibody structure and sequence by integrating a structure predictor with an antibody-specific protein language model to perform de novo design of functional complementarity-determining regions (CDRs) onto a user-specified structural framework. When tested against four diverse protein targets, Germinal successfully designed functional antibodies across all targets and binder formats, testing only 43-101 designs for each antigen. Validated designs also exhibited robust expression in mammalian cells and high sequence and structural novelty. We provide open-source code and full computational and experimental protocols to facilitate wide adoption. Germinal represents a milestone in efficient, epitope-targeted de novo antibody design, with notable implications for the development of molecular tools and therapeutics.

28 March 2025 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
XZXiaowei Zhang
Xiaowei Zhang
LFLuis Santiago Mille Fragoso
Luis Santiago Mille Fragoso
KKK. Eerik Kaseniit
K. Eerik Kaseniit
ALArden P. Lee
Arden P. Lee
MZMeng Zhang
Meng Zhang
XGXiaojing J. Gao
Xiaojing J. Gao

5 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
XZXiaowei Zhang
Xiaowei Zhang
LFLuis Santiago Mille Fragoso
Luis Santiago Mille Fragoso
KKK. Eerik Kaseniit
K. Eerik Kaseniit
CCConnor C. Call
Connor C. Call
MZMeng Zhang
Meng Zhang
XGXiaojing J. Gao
Xiaojing J. Gao
Inspired by the power of transcriptional synthetic receptors and hoping to complement them to expand the toolbox for cell engineering, we establish LIDAR (Ligand-Induced Dimerization Activating RNA editing), a modular post-transcriptional synthetic receptor platform that harnesses RNA editing by ADAR. LIDAR is compatible with various receptor architectures in different cellular contexts, and enables the sensing of diverse ligands and the production of functional outputs. Furthermore, LIDAR can sense orthogonal signals in the same cell and produce synthetic spatial patterns, potentially enabling the programming of complex multicellular behaviors. Finally, LIDAR is compatible with compact encoding and can be delivered as synthetic mRNA. Thus, LIDAR expands the family of synthetic receptors, holding the promise to empower basic research and therapeutic applications.

17 July 2025 in bioRxiv
Verified
Preprint
Open access
XZXiaowei Zhang
Xiaowei Zhang
WLWenhui Sophia Lu
Wenhui Sophia Lu
BVBen Viggiano
Ben Viggiano
KRKevin Reynolds
Kevin Reynolds
SBSophia Burick
Sophia Burick
XGXiaojing J. Gao
Xiaojing J. Gao
Proteins evolved for native biological contexts often fail when deployed in new cellular environments or therapeutic settings. We present ProVADA, a test-time framework that steers a pretrained protein generator toward externally defined properties while preserving functional constraints. Its Mixture-Adaptation Directed Annealing sampler combines coordinated mutations, population selection, and annealing to navigate rugged objective landscapes. Experimentally, ProVADA converted secreted human renin into an active, drug-inhibitable cytosolic protease and extensively deimmunized two murine single-chain antibody fragments to reduce HLA visibility while retaining antigen recognition. ESCAPE-seq measurements confirmed substantial depletion of HLA-I binder peptides across alleles. Deimmunized FMC63 variants retained CAR-T-cell killing and showed fewer binders than a tested humanized comparator. Together, these results demonstrate that broad sequence redesign can adapt functional proteins to non-native biological contexts.